| Current Price | $1.07 | Mkt Cap | $186.6M |
|---|---|---|---|
| Open | $1.08 | P/E Ratio | -7.62 |
| Prev. Close | $1.07 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $1.07 - $1.11 | Volume | 516,318 |
| 52-Wk Range | $0.71 - $2.04 | Avg. Daily Vol. | 1,162,503 |
The Company is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases.
| Current Price | $1.07 | Mkt Cap | $186.6M |
|---|---|---|---|
| Open | $1.08 | P/E Ratio | -7.62 |
| Prev. Close | $1.07 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $1.07 - $1.11 | Volume | 516,318 |
| 52-Wk Range | $0.71 - $2.04 | Avg. Daily Vol. | 1,162,503 |
The best Bull and Bear pitches based on recency and number of recommendations.
Obviously this puts them in a tough spot with Fostamatinib but they do have a few bullets left to fire in 2013 along with some cash that was raised at the end of 2012. I think the offering priced at 9.50. Not saying I have much of a valuation model… More
I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!
Read the most recent pitches from players about RIGL.
Recs
emtking
(49.00)
Submitted: 12/28/2022 2:04:51 PM :
Start Price:
$1.27
NASDAQ:RIGL Score:
+78.32
FDA approval of a new cancer drug MONTHS ahead of schedule. This is the first time in my life I have heard of this. It went on sale in Q4 of 2022, at a price of something crazy like $33,000 per year. They just started another drug trial. I think this makes them a takeover target. They were at risk of delisting when the FDA approval announcement came out. They were around $0.63 per share then, and were being piled on by shorts. They made the 10+ days in a row above $1 per share, and now trade about 100% above that 52 week low. Although still on shaky ground in the worst stock market in 14 years, RIGL looks to be making a strong base above $1/sh and headed higher in 2023. Adding shares in Roth, Traditional IRA, and Calls in non qualified account. 1 year average analyst price target is above $3/share.
Recs
Bigsef77
(48.50)
Submitted: 7/14/2020 5:45:53 PM :
Start Price:
$2.56
NASDAQ:RIGL Score:
-150.23
COVID trials
Recs
raspoutine
(< 20)
Submitted: 6/4/2019 3:41:48 PM :
Start Price:
$2.14
NASDAQ:RIGL Score:
-112.28
indication for their approved drug.
Find the members with the highest scoring picks in RIGL.
qubit15 (26.44) Score: +555.10
The Score Leader is the player with the highest score across all their picks in RIGL.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| qubit15 | 26.44 | 1/21/2009 |
|
NS | $6.95 | -84.60% | +470.50% | +555.10 | 0 Comment | |
| robo2011 | 21.60 | 11/17/2008 |
|
NS | $6.53 | -83.61% | +442.30% | +525.91 | 0 Comment | |
| anticitradeshort | 28.14 | 4/20/2009 |
|
NS | $6.43 | -83.36% | +439.34% | +522.70 | 0 Comment | |
| cybob2000 | 52.12 | 10/23/2008 |
|
3W | $15.64 | -93.16% | +418.83% | +511.99 | 0 Comment | |
| schwah8 | 97.80 | 10/13/2008 |
|
NS | $18.26 | -94.14% | +395.85% | +489.99 | 0 Comment | |
| EV38biotech | < 20 | 11/5/2008 |
|
5Y | $8.60 | -87.56% | +376.05% | +463.61 | 0 Comment | |
| Mynx828 | 64.54 | 9/17/2009 |
|
5Y | $7.45 | -85.64% | +328.09% | +413.73 | 0 Comment | |
| longtermgrowth09 | 60.55 | 12/17/2009 |
|
5Y | $8.97 | -88.07% | +312.39% | +400.46 | 0 Comment | |
| darksider389 | 84.22 | 7/7/2008 |
|
3M | $21.97 | -95.13% | +278.41% | +373.54 | 0 Comment | |
| flats66 | 65.20 |
|
|
3Y | $22.71 | -95.29% | +268.43% | +363.72 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
